{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:35:30Z","timestamp":1773779730454,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":284,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is no strong evidence supporting brentuximab vedotine (BV) efficacy as a salvage regimen for relapsed\/refractory Hodgkin\u2019s lymphoma (R\/R HL) patients before autologous hematopoietic cell transplantation (auto\u2010HCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed multicenter retrospective analysis of efficiency of treatment with the BV monotherapy as salvage regimen versus standard salvage chemotherapy (sCT) in 44 patients with R\/R HL from a high\u2010risk group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010six patients (59.1%) had primary refractory disease. Nineteen patients (43.2%) received BV salvage treatment before auto\u2010HCT, and 12 (63.6%) achieved complete response (CR) that counts 27.3% of the whole study cohort. There was no difference in the CR rate, 2\u2010year progression\u2010free survival, and 2\u2010year overall survival after BV salvage and sCT (63.2% vs. 60%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.35; 88.2% vs. 80.7%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.655; 94.1% vs. 100%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.735, respectively). There was no difference in neuropathy of all grades, including Grades 2\u20103 between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The BV as a salvage treatment showed quite high efficiency. Despite a worse clinical characteristic of the BV group, there were no significant differences in the outcomes of the auto\u2010HCT with respect to the salvage regimen (BV versus sCT) used before auto\u2010HCT. Our results suggest that BV before auto\u2010HCT in patients refractory to standard 2nd line treatment equalizes their prognosis to the patient sensitive to standard CT with the same tolerance and toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/ah\/3573471","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:10:03Z","timestamp":1760328603000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-3110","authenticated-orcid":false,"given":"Kateryna","family":"Filonenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-193X","authenticated-orcid":false,"given":"Yana","family":"Stepanishyna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4294-2492","authenticated-orcid":false,"given":"Nazar","family":"Shokun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3094-8867","authenticated-orcid":false,"given":"Arina","family":"Martynchyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevhen","family":"Kushchevyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Kriachok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,12]]},"reference":[{"key":"e_1_2_13_1_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679407"},{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.9410"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08938-9"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2619-9"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15539"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz009"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"e_1_2_13_11_2","article-title":"Current Use and Outcomes of Hematopoietic Stem Cell Transplantation: CIBMTR US Summary Slides","author":"Auletta J. J.","year":"2021","journal-title":"CIBMTR"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.018"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2164195"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx791"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138666"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26827"},{"key":"e_1_2_13_17_2","first-page":"460","article-title":"P451 Efficacy and Safety of Brentuximab Vedotin as a Salvage Treatment Before Autologous SCT in Patients With Relapsed and Refractory Hodgkin Lymphoma-Ukrainian Experience","volume":"58","author":"Filonenko K.","year":"2023","journal-title":"Bone Marrow Transplantation"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ah\/3573471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ah\/3573471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ah\/3573471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:21:30Z","timestamp":1773768090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ah\/3573471"}},"subtitle":[],"editor":[{"given":"Suraiya","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/ah\/3573471"],"URL":"https:\/\/doi.org\/10.1155\/ah\/3573471","archive":["Portico"],"relation":{},"ISSN":["1687-9104","1687-9112"],"issn-type":[{"value":"1687-9104","type":"print"},{"value":"1687-9112","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"3573471"}}